DNA-nanorobot-guided thrombin-inducing tumor infarction (DNA NanorobotTh-ITI) is emerging as a powerful therapeutic strategy for treatment of solid cancers. The technology represents a major advance in the application of DNA nanotechnology for anticancer therapy. More importantly, the technology is being translated from preclinical studies to the clinic owing to its promising anticancer effects with fewer toxicities demonstrated in preclinical settings. However, despite these beneficial effects of the technology, it is important to point out that some important potential clinical concerns remain to be addressed. Here, we raise these clinical concerns along with these beneficial effects of the technology. Hopefully, these newly raised potential clinical concerns could drive forward research in this field to expedite its clinical translation.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.drudis.2020.03.005, hdl.handle.net/1765/126469
Journal Drug Discovery Today
Citation
Zheng, K. (Kang), Kros, J.M, Li, J. (Jin), & Zheng, P.P. (2020). DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. Drug Discovery Today. doi:10.1016/j.drudis.2020.03.005